Health Economics›CNS lymphoma›Upfront therapy non-randomized or retrospective data

Upfront therapy non-randomized or retrospective data

CNS lymphoma · 14 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
R-MP Variant #01 Partial	—	R 82 882	42d	—	—	—	—	—
R-MCP (CCNU) Variant #01 Partial	—	R 47 494	43d	—	—	—	—	—
MATRix-RICE Variant #01 Partial	—	R 41 110	21d	—	—	—	—	—
Nordic Regimen, younger patients Variant #01 Partial	—	R 23 611	21d	—	—	—	—	—
Nordic Regimen, older patients Variant #01 Partial	—	R 21 903	21d	—	—	—	—	—
MT-R Variant #01	—	R 15 566	14d	—	—	—	—	—
Methotrexate and Rituximab Variant #01	—	R 12 072	14d	—	—	—	—	—
Methotrexate-Cytarabine Variant #01	—	R 4 515	30d	—	—	—	—	—
MPV N/A - intrathecal component	—	R 1 180	14d	—	—	—	—	—
Lomustine, Methotrexate, Procarbazine, Methylprednisolone N/A - intrathecal component	—	R 70	45d	—	—	—	—	—
Lomustine, Methotrexate, Procarbazine N/A - intrathecal component	—	R 18	45d	—	—	—	—	—
R-MPV N/A - intrathecal component	—	R 0	14d	—	—	—	—	—
MVBP N/A - intrathecal component	—	R 0	—	—	—	—	—	—
Methotrexate-Cytarabine and Thiotepa N/A - secondary systemic drug	—	R 0	10d	—	—	—	—	—

14 of 14 regimens shown